• Intern and Resident, Internal Medicine, Emory University Affiliated Hospitals, Atlanta, Georgia
• Resident, Ophthalmology, Emory University Affiliated Hospitals, Atlanta, Georgia
• Fellow, Medical Retina, Moorfields Eye Hospital, London, England
• Fellow, Vitreoretinal Surgery, Moorfields Eye Hospital, London, England

• 1992-94 - General Ophthalmology Private Practice, Columbia, SC
• 1995-99 - Carolina Eye Consultants, LLC, Practice limited to diseases and surgery of the retina and vitreous, Columbia, SC
• 2000 - Assistant Professor of Ophthalmology, Vitreoretinal Diseases and Surgery, Department of Ophthalmology, University of South Carolina School of Medicine, Columbia, SC
• 2001 - Palmetto Retina Center, LLC, Practice limited to diseases and surgery of the retina and vitreous, Columbia, SC

• 1980-82 - Student Government, Washington and Lee University
• 1981 - Phi Beta Kappa, Washington and Lee University
• 1982 - Omicron Delta Kappa, Washington and Lee University
• 1984-86 - Admissions Committee, Emory University School of Medicine
• 1986-91 - Class Agent, Emory University School of Medicine Alumni Association
• 1995 - Participant, Columbia Medical Society Mini-Internship Program
• 1998-99 - Secretary, Medical Journal Club
• 2000 - Vice-President, Medical Journal Club
• 2001 - President, Medical Journal Club
• 2000-02 - Class Agent, Washington and Lee University Annual Fund

• 1982- Member, American Medical Association
• 1988-1992 - Member, American Academy of Ophthalmology
• 1991- Member, Emory Eye Alumni Association
• 1992- Fellow, American Academy of Ophthalmology
• 1992- Member, Oxford Ophthalmological Society,
• 1992- Member, Moorfields Eye Hospital Alumni Association
• 1992- Member, South Carolina Medical Association
• 1992- Member, Columbia Medical Society
• 1992- Member, Central South Carolina Ophthalmological Society
• 1992- Member, South Carolina Society of Ophthalmology
• 1995- Member, Association for Research in Vision and Ophthalmology
• 1996-97 - Executive Committee, South Carolina Society of Ophthalmology
• 1988-2000 - Associate Member, American College of Surgeons
• 2000- Fellow, American College of Surgeons
• 2000- Member, American Society of Retinal Specialists (Vitreous Society)
• 2000- Candidate, Club Jules Gonin

Board Certification

1993 - American Board of Ophthamology

Hospital Appointments

• 1992 - Providence Hospital, Columbia, SC - Chief, Department of Ophthalmology 1994; Vice-Chief, Department of Ophthalmology 2003
• 1992 - Palmetto Richland Memorial Hospital, Columbia, SC - Chief, Department of Ophthalmology, 1996
• 1992 - Palmetto Baptist Medical Center, Columbia, SC
• 1992-2002 - VA Medical Center, Columbia, SC
• 2001 - Lexington Medical Center, West Columbia, SC

• Clinical Instructor, Emory University School of Medicine, Department of Ophthalmology, 1992-1998, Atlanta, GA
• Clinical Assistant Professor, University of South Carolina School of Medicine, Department of Ophthalmology, 1992-1999, Columbia, SC
• Assistant Professor, Department of Ophthalmology, University of South Carolina School of Medicine, 2000, Columbia, SC

Wells JA, McCarey BE. Three year morphological follow-up of hydrogel intracorneal implants. ARVO Abstracts, May 1987, p.226.

Seedor JA, Walsh GE, Wells JA, et al. Corneas from ventilator supported donors: endothelial morphology and results of a survey. Eye Bank Association of America Abstracts, November 1987.

Holz FG, Wolfensberger TJ, Piguet B, Wells JA, et al. Bilateral macular drusen in age-related macular degeneration: prognosis and risk factors. American Academy of Ophthalmology Annual Meeting 1993, Program Abstracts, p. 62.

Wolin MJ, Wells JA. Acute zonal occult outer retinopathy. North American Neuro-ophthalmology Society Abstracts, February 1994.

Wells JA, Chibber R, Kohner E, Gregor ZJ. Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) levels are elevated in the vitreous of patients with subretinal neovascularization. ARVO Abstracts, May 1995.

Pitts JF, Schwartz SD, Wells JA, Gregor ZJ. Trans-scleral indirect argon laser drainage of subretinal fluid. The Royal College of Ophthalmologists Annual Meeting Abstracts, May 1995, p. 96.

Wells JA, Gregor ZJ. Surgical treatment of full-thickness macular holes using autologous serum. The Royal College of Ophthalmologists Annual Meeting Abstracts, May 1995, p. 28.

Wells JA, Gray RH, Kinsella F, Orr GM, Arden GB, Gregor ZJ. Fellow eye involvement in patients with macular holes: incidence and identification of eyes at risk. American Academy of Ophthalmology Annual Meeting 1995, Program Abstracts, p. 148.

Gregor ZJ, Ruckmann AV, Schmidt KG, Wells JA. Diagnosing and staging of macular holes using autofluorescence imaging. ARVO Abstracts, April 1996.

Ezra E, Wells JA, Charteris DG, Aylward GW, Gregor ZJ. Macular hole surgery with and without autologous serum: a prospective study of 109 consecutive eyes. ARVO Abstracts, April 1996.

Boada R, Cady R, Wells JA, Clark WL, Goins C, Saperstein D. Tissue plasminogen activator (t-PA) assisted subfoveal hemorrhage displacement surgery. ARVO Abstracts May 2002.

Posters

Wells JA, McCarey BE. Three-year morphological follow-up of hydrogel intracorneal implants. ARVO Annual Meeting, Sarasota, May 1987.

Pitts JF, Schwartz SD, Wells JA, Gregor ZJ. Trans-scleral indirect argon laser drainage of subretinal fluid. The Royal College of Ophthalmologists Annual Meeting, Birmingham, May 1995.

Wells JA, Grey RB, Arden GB, Gregor ZJ. Fellow eye macular holes: incidence and risk factors. American Academy of Ophthalmology Annual Meeting, Atlanta, October 1995.

Wells JA, Ezra EM, Gregor ZJ. XXI Meeting of the Club Jules Gonin, September 1998.

Wells JA. Reticular pseudodrusen in age-related macular degeneration. XXII Meeting of the Club Jules Gonin, Taormina, Sicily, September 2000.

Publications

Bechara SJ, Grossniklaus HE, Waring GO, Wells JA. Keratoconus associated with posterior polymorphous dystrophy. Am J Ophthalmol 1991; 112: 729-31.

Wells JA, Wroblewski J, Keen J, et al. Mutations in the human retinal degeneration slow (RDS) gene can cause either retinitis pigmentosa or macular dystrophy. Nature Genetics 1993; 3: 213-17.

Piguet B, Wells JA, Palmvang I, et al. Age-related Bruch's membrane change: a clinical study of the relative role of heredity and the environment. Br J Ophthalmol 1993; 77: 400-03.

Wroblewski JJ, Wells JA, Eckstein A, et al. Macular dystrophy associated with mutations at codon 172 in the human retinal degeneration slow (RDS) gene. Ophthalmology 1994; 101: 12-22.

Wells JA, Ellerine N, Fernhoff P, Waring GO. Corneal opacities in spondyloepiphyseal dysplasia tarda. Cornea 1994; 13: 280-83.

Wroblewski JJ, Wells JA, Eckstein A, et al. Ocular findings associated with a three base pair deletion in the peripherin-RDS gene in autosomal dominant retinitis pigmentosa. Br J Ophthalmol 1994; 78: 831-36.

Holz FG, Wolfensberger TJ, Piguet B, Wells JA, et al. Bilateral macular drusen in age-related macular degeneration: prognosis and risk factors. Ophthalmology 1994; 101: 1522-8.

Wells JA, Murthy R, Chibber R, Nunn A, Molinatti PA, Kohner EM, Gregor ZJ. Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. Br J Ophthalmol 1996; 80: 363-366.

Pitts JF, Schwartz SD, Wells JA, Gregor ZJ. Indirect argon laser drainage of subretinal fluid. Eye. 1996; 10 (Pt 4): 465-468.
Wells JA, Gregor ZJ. Surgical treatment of full-thickness macular holes using autologous serum. Eye. 1996; 10 (Pt 5): 593-599.

Ezra E, Wells JA, Gray RH, Kinsella FM, Orr GM, Grego J, Arden GB, Gregor ZJ. Incidence of idiopathic full-thickness macular holes in fellow eyes. A five-year prospective natural history study. Ophthalmology. 1998 Feb; 105 (2): 353-359.

Eckstein MA, Wells JA, Gregor ZJ. Surgical removal of non-age-related subfoveal choroidal neovascular membranes. Eye. 1998; 12 (Pt 5): 775-780.

Presentations

Wells JA, Sternberg P, Meredith TA. Acute dappled pigment epitheliopathy. Residents' Day, Emory Eye Center, Atlanta, June 1990.

Wells JA, Sternberg P, Stulting RD. Pseudomonas scleritis and keratoscleritis. Residents' Day, Emory Eye Center, Atlanta, June 1991.

Wells JA. Recent advances in the genetics of retinal degenerations. Grand Rounds, South Carolina Eye Institute, Columbia, December 1992.

Wells JA, Bird AC. Retinal degenerations and the peripherin-RDS gene. Lecture, Duke Eye Center, Durham, February 1993.

Wells JA. Retinitis pigmentosa: new genetic findings. Southeastern Genetic Cytotechnologists Meeting, Columbia, September 1993.

Wells JA. Major eye diseases of the elderly. South Carolina Commission for the Blind Seminar, Columbia, November 1993.

Wells JA. Acute zonal occult outer retinopathy. Eighth Southeastern Vitreoretinal Seminar, Atlanta, February 1994.

Wells JA. Laser treatment of subretinal neovascularization. Grand Rounds, South Carolina Eye Institute, Columbia, May 1994.

Wells JA, Gregor ZJ. Idiopathic full-thickness macular holes. Vitreoretinal Teaching Conference, Moorfields Eye Hospital, London, September 1994.

Wells JA, Hiscott PA, Luthert P, Gregor ZJ. Surgical removal of subfoveal membranes. Moorfields Alumni Meeting, London, January 1995.

Wells JA, Gregor ZJ. The vanishing nucleus: management of dislocated crystalline lenses. Moorfields Eye Hospital Grand Rounds, London, February 1995.

Wells JA, Gregor ZJ. Laser treatment of retinal disease. City College Optometry Course, London, February 1995.

Wells JA, Chibber R, Kohner E, Gregor ZJ. Vascular endothelial growth factor/ vascular permeability factor (VEGF/VPF) levels are elevated in the vitreous of patients with subretinal neovascularization. ARVO Annual Meeting, Fort Lauderdale, May 1995.

Wells JA, Gregor ZJ. Surgical treatment of full-thickness macular holes using autologous serum. Royal College of Ophthalmologists Annual Meeting, Birmingham, May 1995.

Wells JA. Fundus autofluorescence in macular diseases. Bert M. Glaser National Retina Institute Feeder Vessel Treatment of CNV Seminar, New York City, NY, June 2002.

Wells JA, Clark WL, Wroblewski JJ. Inferior displacement of submacular hemorrhage. XXIII Meeting of the Club Jules Gonin, Lausanne, Switzerland, September 2002.

Wells JA. Understanding age-related macular degeneration. Palmetto Health Baptist Hospital Continuing Medical Education Lunch & Learn, Columbia, SC, October 16, 2003.

Clinical Trials

Clinical Research: Principal Investigator

2001-2005 - A phase II randomized, controlled, double-masked, dose-finding, multi-center, comparative trial, in parallel groups, to establish the safety and preliminary efficacy of intravitreal injections of EYE001 (anti-VEGF pegylated aptamer), given every 6 weeks for 12 to 30 weeks to patients with clinically significant macular edema (CSME) involving the center of the macula.

Sponsor: Eyetech Pharmaceuticals, Inc.

2001-present - A phase II/III randomized, double-masked, controlled, dose-ranging, multi- center comparative trial, in parallel groups, to establish the safety and efficacy of intravitreal injections of EYE001 (anti-VEGF pegylated aptamer) given every 6 weeks for 54 weeks, in patients with exudative age-related macular degeneration (AMD).

Sponsor: Eyetech Pharmaceuticals, Inc.

2002-present - A randomized, double-masked, multi-center trial of the safety, tolerability and pharmacokinetics of 1mg/eye and 3 mg/eye intravitreal injections of pegaptanib sodium (anti-VEGF pegylated aptamer) given every 6 weeks for 54 weeks, in patients with exudative age-related macular degeneration (AMD).

Sponsor: Eyetech Pharmaceuticals, Inc.

2003-present - Diabetic Retinopathy Clinical Research Network Protocol 1-A: A pilot study of laser photocoagulation for diabetic macular edema.

Sponsor: JAEB Center

2004-present - An Evaluation of Efficacy and Safety of Posterior Juxtascleral Administrations of Anecortave Acetate for Depot Suspension (15mg or 30mg) versus Sham Administration in Patients (Enrolled in Study “A” or Study “B”) at Risk for Developing Sight Threatning Choroidal Neovascularization (CNV) Due to Exudative Age Related Macular Degeneration (AMD), Protocol Number C-02-60.

Sponsor: Alcon Pharmaceuticals

2004-present - A Phase II prospective, randomized, double-masked, sham-controlled, dose-ranging, multi-center trial to assess the effect of pegaptanib sodium on foveal thickening in patients with exudative subfoveal age-related macular degeneration (AMD).

Sponsor: Eyetech Pharmaceuticals

2004-present - A Phase II randomized, double-masked, multi-center trial, in groups, to determine the safety, efficacy and pharmacokinetics of intravitreous injections of pegaptanib sodium compared to sham injection for 30 weeks in patients with recent vision loss due to macular edema secondary to CRVO.

Sponsor: Eyetech Pharmaceuticals

2004-present - A Phase 1/2 Randomized, Masked, Single and Multiple-Dose, Sequential Dose-Escalation Study of the Safety and Efficacy of AG-013958 in Subjects with Subfoveal Choroidal Neovascularization Associated with Age-related Macular Degeneration.

Sponsor: Pfizer Inc.

2004-present - A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema to determine whether intravitreal triamcinolone injections at doses of 1 mg or 4 mg produce greater benefit, with an acceptable safety profile, than macular laser photocoagulation in the treatment of diabetic macular edema and will also compare the efficacy and safety of the 1 mg and 4 mg triamcinolone doses.

Sponsor: Diabetic Retinopathy Clinical Research Network

2004-present - The Standard Care vs. Corticosteroid for Retinal Vein Occlusion Study. Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide with Standard Care to Treat Macular Edema: One for Central Retinal Vein Occlusion and One for Branch Retinal Vein Occlusion (SCORE Study).

Sponsor: National Eye Institute

2005-present - A phase 4, randomized, active controlled, double masked, single dummy, multi-center comparative trial, in parallel groups, to compare the safety and efficacy of intravitreous injections of Macugen given every 6 weeks for up to 102 weeks, plus sham photodynamic therapy (PDT), to Macugen plus PDT with Visudyne in subjects with predominantly classic subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).

Sponsor: Eyetech Pharmaceuticals

2005-present - DRCR Protocol C: Temporal variation in optical coherence tomography measurements of retinal thickening in diabetic macular edema.

Sponsor: Diabetic Retinopathy Clinical Research Network.

Clinical Research: Sub-Investigator

2003-present - A phase III, multicenter, randomized, double-masked, active treatment-controlled study of the efficacy and safety of rhuFab (ranibizumab) compared with Verteporfin (Visudyne) photodynamic therapy in subjects with predominantly classic subfoveal neovascular age-related macular degeneration.

Sponsor: Genentech

2004-present - A Six-Month Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial (with Six-Month Open-Label Extension) to Assess the Safety and Efficacy of 700ug and 350ug Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS Applicator System) in the Treatment of Patients with Macular Edema Following Central Retinal Vein Occlusion or Branch Retinal Vein Occlusion.

Sponsor: Allergan

Collaborating Physician

2002-present - Study of Diabetic Retinopathy in the Family Investigation of Nephropathy and Diabetes (FIND)
Sponsor: National Eye Institute